Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Current Assets (2022 - 2025)

NewAmsterdam Pharma's Current Assets history spans 4 years, with the latest figure at $675.7 million for Q4 2025.

  • For Q4 2025, Current Assets fell 21.74% year-over-year to $675.7 million; the TTM value through Dec 2025 reached $675.7 million, down 21.74%, while the annual FY2025 figure was $675.7 million, 21.74% down from the prior year.
  • Current Assets for Q4 2025 was $675.7 million at NewAmsterdam Pharma, down from $732.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $863.4 million in Q4 2024 and bottomed at $346.8 million in Q4 2023.
  • The 4-year median for Current Assets is $581.8 million (2024), against an average of $603.4 million.
  • The largest annual shift saw Current Assets dropped 24.15% in 2023 before it surged 148.97% in 2024.
  • A 4-year view of Current Assets shows it stood at $457.2 million in 2022, then dropped by 24.15% to $346.8 million in 2023, then soared by 148.97% to $863.4 million in 2024, then decreased by 21.74% to $675.7 million in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Current Assets are $675.7 million (Q4 2025), $732.3 million (Q3 2025), and $769.8 million (Q2 2025).